News tonight3 Dec 2021 18:57
DNCA Finance +5% holding is funded by TA Associates
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, has been informed that DNCA Finance's interest in ordinary shares of 25p each in the Company ("Ordinary Shares") totals 22,625,000 Ordinary Shares representing 5.02% of the Company's issued share capital.